Le Lézard
Classified in: Health, Science and technology
Subject: CALENDAR OF EVENTS

CohBar to Announce 2018 Third Quarter Financial Results and Host Conference Call on November 14, 2018


MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, announced today that it will release its third quarter 2018 financial results after the market closes on Wednesday, November 14, 2018, followed by a conference call on which the company's management will discuss the results and provide a company update.

Details for the Conference Call:

Date: November 14, 2018
Time: 2:00 p.m. (Pacific Time)

Conference Audio

We kindly request that you call into the conference audio approximately 10 minutes before the start time so that we can begin promptly.

An audio replay of the call will be available beginning at 5:00 p.m. Pacific Time on November 14, 2018, through 9:00 p.m. Pacific Time on December 5, 2018. To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID No. 1659879. The audio replay will also be available at www.cohbar.com from November 14, through December 5, 2018.

About CohBar

CohBar is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome which regulate metabolism and cell death, and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases with underlying metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), obesity, Type 2 diabetes, cancer, and cardiovascular and neurodegenerative diseases. To date, the company and its founders have discovered more than 100 MDPs. For additional company information, please visit www.cohbar.com.

Investor and Media Contacts:
Jeff Biunno, CFO
CohBar, Inc.
(650) 446-7888, Option 3
[email protected]

Joyce Allaire
LifeSci Advisors, LLC
[email protected] 


These press releases may also interest you

at 00:50
Flash News: OKX Wallet Now Integrated with XION, a User-First Layer 1 Blockchain
OKX, a leading Web3 technology company, has issued updates for April 25, 2024. OKX Wallet Now Integrated with XION, a User-First ...

at 00:30
Wego and Tourism Authority of Thailand Partner for The Fourth Consecutive Year, Showcasing the Beauty of Thailand
Wego, the largest online travel marketplace in the Middle East and North Africa (MENA), is thrilled to announce its continued partnership with the Tourism Authority of Thailand (TAT) for the fourth consecutive year, showcasing the unparalleled beauty...

at 00:30
ENOC Group Partners with Loyyal to Enhance 'YES' Rewards Members' Experience
ENOC Group, a leading integrated global energy player, has appointed the innovative technology loyalty partner, Loyyal, to integrate Access Point, their self-service platform, into the Group's rewards programme. This move will revolutionize the 'YES'...

at 00:05
Systal Technology Solutions Expands International Operations with US Headquarters Launch
Systal Technology Solutions, a global managed network, cloud, and security transformation specialist, today announces the opening of its new Network Operations Center (NOC) in Tampa, Florida. This marks the latest milestone in Systal's recent growth...

at 00:05
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
ImmunityBio, Inc. , an immunotherapy company, today announced positive overall survival results in the QUILT 3.055 study of 2nd- and 3rd-line NSCLC patients who progressed after checkpoint inhibitor therapy (pembrolizumab, nivolumab, or atezolizumab)...

at 00:01
PROFITS FOR U.S. HOME SELLERS DECLINE AGAIN IN FIRST QUARTER OF 2024 AS PRICES FALL
ATTOM, a leading curator of land, property, and real estate data, today released its first-quarter 2024 U.S. Home Sales Report, which shows that profit margins on median-priced single-family home and condo sales in the United States decreased to 55.3...

More news about Science and technology...


News published on and distributed by: